TR200102448T2 - COPD tedavisi için kontrollu salma formülasyonu. - Google Patents

COPD tedavisi için kontrollu salma formülasyonu.

Info

Publication number
TR200102448T2
TR200102448T2 TR2001/02448T TR200102448T TR200102448T2 TR 200102448 T2 TR200102448 T2 TR 200102448T2 TR 2001/02448 T TR2001/02448 T TR 2001/02448T TR 200102448 T TR200102448 T TR 200102448T TR 200102448 T2 TR200102448 T2 TR 200102448T2
Authority
TR
Turkey
Prior art keywords
release formulation
controlled release
copd treatment
copd
treatment
Prior art date
Application number
TR2001/02448T
Other languages
English (en)
Inventor
G. Faulkner Patrick
J.Lucca Jaime
J. Wrzosek Thaomas
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200102448T2 publication Critical patent/TR200102448T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bu bulus, astim veya COPD veya benzeri gibi bir enflamatuar hastaligin tedavisinde bir PDE4 inhibitörü iletmek üzere tasarlanmis bir kontrollü veya gecikmeli salma formülasyonu ile ilgilidir.
TR2001/02448T 1999-02-23 2000-02-22 COPD tedavisi için kontrollu salma formülasyonu. TR200102448T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12129199P 1999-02-23 1999-02-23

Publications (1)

Publication Number Publication Date
TR200102448T2 true TR200102448T2 (tr) 2003-03-21

Family

ID=22395738

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02448T TR200102448T2 (tr) 1999-02-23 2000-02-22 COPD tedavisi için kontrollu salma formülasyonu.

Country Status (29)

Country Link
US (1) US20030211152A1 (tr)
EP (1) EP1154758A4 (tr)
JP (1) JP2002537320A (tr)
KR (1) KR20010112279A (tr)
CN (1) CN1195496C (tr)
AR (1) AR028986A1 (tr)
AU (1) AU3501500A (tr)
BG (1) BG105905A (tr)
BR (1) BR0008382A (tr)
CA (1) CA2366747A1 (tr)
CO (1) CO5150233A1 (tr)
CZ (1) CZ20013025A3 (tr)
EA (1) EA200100906A1 (tr)
HK (1) HK1043045A1 (tr)
HU (1) HUP0200134A3 (tr)
ID (1) ID29792A (tr)
IL (1) IL144603A0 (tr)
MA (1) MA25386A1 (tr)
MY (1) MY121142A (tr)
NO (1) NO20014049L (tr)
NZ (1) NZ527716A (tr)
OA (1) OA11836A (tr)
PE (1) PE20001496A1 (tr)
PL (1) PL350287A1 (tr)
SK (1) SK12072001A3 (tr)
TR (1) TR200102448T2 (tr)
TW (1) TWI224013B (tr)
WO (1) WO2000050011A1 (tr)
ZA (1) ZA200106803B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002446A0 (en) * 1999-10-29 2002-03-31 Smithkline Beecham Corp Method for administering a phosphodiesterase 4 inhibitor.
WO2002094321A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
WO2002094320A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Therapeutic compositions for repairing chondropathy
US20050014762A1 (en) * 2001-09-19 2005-01-20 Rolf Beume Combination
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
BR0318535A (pt) * 2003-09-30 2006-09-12 Lupin Ltd composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
NZ553587A (en) * 2004-08-13 2010-12-24 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmacutically acceptable salt thereof
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途
MX2021008536A (es) * 2019-01-15 2021-11-12 Union Therapeutics As Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa.
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636568A (tr) * 1961-01-31
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
TWI224013B (en) 2004-11-21
CN1347314A (zh) 2002-05-01
NO20014049D0 (no) 2001-08-20
PL350287A1 (en) 2002-12-02
NZ527716A (en) 2005-03-24
ZA200106803B (en) 2002-08-19
IL144603A0 (en) 2002-05-23
SK12072001A3 (sk) 2002-01-07
BG105905A (bg) 2002-04-30
JP2002537320A (ja) 2002-11-05
MY121142A (en) 2005-12-30
MA25386A1 (fr) 2002-04-01
AR028986A1 (es) 2003-06-04
OA11836A (en) 2005-08-22
CN1195496C (zh) 2005-04-06
US20030211152A1 (en) 2003-11-13
ID29792A (id) 2001-10-11
CA2366747A1 (en) 2000-08-31
HUP0200134A3 (en) 2003-03-28
NO20014049L (no) 2001-10-22
KR20010112279A (ko) 2001-12-20
EP1154758A1 (en) 2001-11-21
WO2000050011A1 (en) 2000-08-31
EA200100906A1 (ru) 2002-02-28
AU3501500A (en) 2000-09-14
CO5150233A1 (es) 2002-04-29
HUP0200134A2 (hu) 2002-05-29
BR0008382A (pt) 2002-02-05
PE20001496A1 (es) 2001-02-08
HK1043045A1 (zh) 2002-09-06
EP1154758A4 (en) 2007-09-05
CZ20013025A3 (cs) 2002-07-17

Similar Documents

Publication Publication Date Title
DZ3186A1 (fr) Ptéridinones utilisées comme inhibiteurs de kinase.
DE60035356D1 (de) Faktor ix/faktor ixa aktivierende antikörper
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
MXPA03001511A (es) Imidazol-5-il-2-amino-pirimidinas como agentes para la inhibicion de la proliferacion celular.
DK1373259T3 (da) Pyridazinonaldosereduktaseinhibitorer
DK1553929T3 (da) Sammensætning med kontrolleret frigivelse.
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
EP1526120A3 (en) Concrete surface retarders
ZA200108016B (en) Pyrazolobenzodiazephines as CDK2 inhibitors.
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
EE200100397A (et) Kompositsioonid inflammatoorse reaktsiooni käitluseks
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
ECSP055888A (es) Derivados de aril-quinazolin/aril-2-amino-fenil metanona que promueven la liberación de la hormona paratiroides.
WO2001010425A3 (de) Verwendung von cgrp-antagonisten und cgrp-release-hemmern zur bekämpfung menopausaler hitzewallungen
MY121142A (en) Controlled release formulation for treating copd
WO2007120333A3 (en) Tetracyclic kinase inhibitors
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
TW200621160A (en) Anti-termite agent
DE60127131D1 (de) Tricyclische imidazopyridine